Mubio Products

	Contact
	Phone : Mail : Address : MUBIO PRODUCTS BV PO Box Oxfordlaan 70 1091 Maastricht Netherlands Web :

	Access center full Profile ?
	Access this center profile and 50 000 others Research centers in more than 30 european countries on Expernova.com ! Sign up or contact us for a personnal online demonstration. This is your Research center ? Sign up for free and complete your profile.

	Partial scientific profile

	Some documents of Mubio Products
	New vaccination therapies for lung cancer LCVAC 2004 - 2006 Subjects : Regional Development, Economic Aspects Contract type : Co-operative research projects Participants : MUBIO PRODUCTS BV NEDERLAND MUBIO PRODUCTS BV Industry MUBIO PRODUCTS BV PO Box 1091 Oxfordlaan 70 NEDERLAND CIRES GMBH DEUTSCHLAND CIRES GMBH Industry CIRES GMBH Emil-Figge Strasse 76A DEUTSCHLAND MEDICAL PROTEOM- CENTER, RUHR-UNIVERSITY BOCHUM DEUTSCHLAND MEDICAL PROTEOM- CENTER, RUHR-UNIVERSITY BOCHUM MEDICAL PROTEOM-CENTER (MPC), RUHR-UNIVERSITY BOCHUM Universitaetsstrasse 150 DEUTSCHLAND UNIVERSITEIT MAASTRICHT/RESEARCH INSTITUTE GROWTH & DEVELOPMENT NEDERLAND UNIVERSITEIT MAASTRICHT/RESEARCH INSTITUTE GROWTH & DEVELOPMENT DEPT.MOLECULAR CELL BIOLOGY- FACULTY OF MEDICINE-RESEARCH INSTITUTE GROW PO Box 616 Universiteitssingel 50 NEDERLAND CIRES Germany CIRES Industry CIRES GMBH Emil-Figge Strasse 76A Germany MUBIO PRODUCTS Netherlands MUBIO PRODUCTS Industry MUBIO PRODUCTS BV PO Box Oxfordlaan 70 Netherlands ONYVAX United Kingdom ONYVAX Industry ONYVAX LIMITED St. Georges Hospital Medical School, Cranmer Terrace United Kingdom Hide objective The aim of this project is to develop new vaccination approaches for the highly needed treatment of lung cancer. Lung carcinoma is the number one killer amongst cancer patients, for which no adequate treatment exists. With conventional therapy, median survival for the subtype of small cell lung cancer (SCLC) is 15 months for limited-stage disease and 9 months for extensive-stage disease, whereas long-term survival is very low.Major obstacles to the successful treatment and eradication of lung cancer are late diagnosis, highly metastatic behaviour, resistance to chemotherapy and the impossibility to surgically remove all cancer cells. In principle, cancer vaccines are a most promising approach for the treatment of cancer in general and lung cancer in particular. Major obstacles in the development of a successful vaccine are the lack of cancer specific antigens to be targeted and the lack of tools to evaluate immunotherapy based on such targets. Source : cordis